Sympathetic overactivity in hypertension: A risk factor for cardiovascular disease

被引：49
作者：
Palatini P. [1 ]
机构：
[1] Dipartimento di Medicina Clinica e Sperimentale, University of Padova, 35128 Padova, via Giustiniani
来源：
Current Hypertension Reports | 2001年 / 3卷 / 1期
关键词：
Left Ventricular Mass; High Heart Rate; Sympathetic Outflow; Moxonidine; Eprosartan;
D O I：
10.1007/s11906-001-0065-z
中图分类号：
学科分类号：
摘要：
Numerous prospective studies have shown that high heart rate is related to the development of hypertension, atherosclerosis, and incidence of cardiovascular events. Experimental studies in monkeys have shown that high heart rate has direct atherogenic effects on the arteries as a result of increased wall stress. However, clustering of several risk factors for coronary artery disease in persons with high heart rate suggests that sympathetic overactivity also accounts for part of the increased cardiovascular morbidity that is observed in persons with tachycardia. Indeed, experimental studies have shown that heightened sympathetic tone can cause obesity, hyperinsulinemia, and insulin resistance, which in the long term can promote the development of atherosclerosis. Through its interaction with plasma insulin, sympathetic overactivity can promote the development of left ventricular hypertrophy. Sympathetic activation can also increase hematocrit and precipitate a procoagulant state. Angiotensin II has an effect both on the central nervous system, enhancing sympathetic outflow, and on the peripheral sympathetic nerves. Among the angiotensin II receptor antagonists, eprosartan showed a particular ability to block presynaptic angiotensin II receptor 1(AT1) receptors at neuro-effector junctions in the sympathetic nervous system, as well as AT1 receptors in blood vessels. This dual action may represent an important advance in treatment of elevated blood pressure. Copyright © 2001 by Current Science Inc.
引用
收藏
页码：S3 / S9
页数：6
相关论文
共 49 条
  • [1] MacMahon S., Peto R., Cutler J., Et al., Blood pressure, stroke, and coronary heart disease, part I: Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias, Lancet, 335, pp. 765-774, (1990)
  • [2] Circulation, 82, pp. 1616-1628, (1990)
  • [3] Palatini P., Julius S., Heart rate and cardiovascular risk, J Hypertens, 15, pp. 1-15, (1997)
  • [4] Collins R., Peto R., MacMahon S., Et al., Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context, Lancet, 335, pp. 827-838, (1990)
  • [5] Kannel W.B., Brand N., Skinner Jr. J.J., Et al., The relation of adiposity to blood pressure and development of hypertension, Ann Intern Med, 67, pp. 48-59, (1967)
  • [6] Julius S., Valentini M., Palatini P., Overweight and hypertension: A two-way street?, Hypertension, 35, pp. 807-813, (2000)
  • [7] Narkiewicz K., Somers V., Mos L., Et al., An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension, J Hypertens, 17, pp. 245-249, (1999)
  • [8] Landsberg L., Krieger D.R., Obesity, metabolism, and the sympathetic nervous system, Am J Hypertens, 2, (1989)
  • [9] Trimarco B., Volpe M., Ricciardelli B., Et al., Studies of the mechanisms underlying impairment of beta- adrenoceptormediated effects in human hypertension, Hypertension, 5, pp. 584-590, (1983)
  • [10] Volpe M., Trimarco B., Ricciardelli B., Et al., Effects of oral salt loading on beta-adrenergic receptor responsiveness in normal and hypertensive subjects, Cardiovasc Res, 16, pp. 732-737, (1982)
12345